Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Etiologic Risk Factors and Global Prevalence

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

ByPeter R. Galle, MD, PhD, Mainz University Medical Center

January 26th 2020

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

HCC Etiologic Risk Factors and Global Prevalence

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma